Victrex plc (LSE:VCT) shares fell 0.98% to 906p in the latest market screen, a 9p decline that values the high-performance polymer specialist at around £797 million.
The move comes after a powerful recovery in the shares. Victrex traded around 670p to 690p after its July update and has since risen sharply, helped by a September profit upgrade and a capital markets event setting out its medium-term plans. Today's dip appears to reflect modest profit-taking ahead of full-year results.
The recovery marks a sharp turnaround from earlier in the year, when a subdued first quarter and weaker medical sales prompted analysts to question whether full-year guidance could be met. The company has now not only met but exceeded its previous expectations.
Key Highlights
In its pre-close trading update on 9 September, Victrex said it now expects FY2026 underlying profit before tax of £45 million to £47 million, ahead of prior guidance of £42 million to £44 million.
Strong momentum continued into the fourth quarter, with growth across end markets led by Aerospace, Value Added Resellers and Electronics, and growth in all regions, particularly Asia Pacific.
In the third quarter, revenue rose 18% to £84.5 million and volumes rose 17%. Victrex remains on track for annualised cost savings of at least £10 million by FY2027.
About Victrex
Victrex (LSE:VCT) is a global leader in high-performance polymer solutions, particularly PEEK, used in demanding applications across aerospace, automotive, electronics, energy and medical markets.
Under new chief executive James Routh, who took over in January 2026, the company is pursuing a Profit Improvement Plan and its "Unlocking Victrex's Potential" strategy.
The September capital markets event focused on the company's addressable market, revised operating model and refreshed leadership team, giving investors more detail on the path to higher margins.
Why Is LSE:VCT Down Today?
The 0.98% decline to 906p does not appear to be linked to a new announcement. Instead, it looks like profit-taking after a strong rally.
The shares have risen significantly since July, increasing expectations ahead of full-year results.
Victrex shares jumped around 18% on the day of its July update, and the subsequent upgrade added further momentum. After such strong gains, investors may be locking in profits.
Key Reasons Behind the Downtick
The first factor is valuation after a big run. The shares are up substantially since the summer.
The second factor is Medical weakness. Medical sales, particularly spine, have been under pressure, though there are signs of stabilisation.
Third, the one-off exceptional loss of around £3 million on a disposal will affect statutory results.
Finally, Victrex remains exposed to cyclical end markets such as automotive and industrial.
Key Growth Catalysts
The biggest catalyst is end-market recovery, particularly aerospace and electronics.
Cost savings of at least £10 million by FY2027 will support margins.
The capital markets event in September set out a roadmap to significantly improved profitability over the medium term.
The company has a refreshed leadership team and a revised operating model, which management believes will drive significant improvement in profitability over the medium term.
Risks
The main risk is a slowdown in key end markets. Pricing pressure and currency movements can affect margins.
Medical market weakness and execution risk on the profit improvement plan are additional considerations.
Victrex's average selling price has been flat, and any pressure on pricing could offset volume growth.
Valuation
At 906p, Victrex is valued at about £797 million, or roughly 17 times the midpoint of its upgraded underlying PBT guidance. The valuation reflects confidence in recovery and margin improvement.
In FY2025, Victrex reported underlying PBT of £46.4 million on revenue of £292.7 million, so the upgraded FY2026 guidance represents a return to similar levels after a transitional year.
Capital Returns
Victrex pays a substantial dividend, including an interim of 13.42p for FY2026. Net debt was £43 million at the end of June.
What Investors Should Watch Next
The key event is the FY2026 results in December. Investors will look for confirmation of upgraded profits, FY2027 guidance and progress on cost savings.
Overall, the 0.98% fall in LSE:VCT to 906p looks like a pause after a strong rally. Upgraded profits, cost savings and recovering demand support the investment case.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...